Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | MARS1 | P56192 | 5/20 | 0.50 |
| ▸ | RPA1 | P27694 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053924 | 0.84 | SMPD1 (0.57) | SMPD1CNR1MEN1KMT2A | |
| SCHEMBL12053872 | 0.79 | CNR2 (0.56) | SMPD1CNR1 | |
| SCHEMBL1738076 | 0.77 | MARS1 (0.64) | SMPD1CNR1MARS1RPA1ALDH1A1 | |
| SCHEMBL15441637 | 0.76 | TRPV4 (0.64) | SMPD1CNR1ALDH1A1MAPTHTT | |
| SCHEMBL28837104 | 0.74 | SMPD1 (1.00) | SMPD1CNR1 | |
| SCHEMBL28837106 | 0.74 | SMPD1 (1.00) | SMPD1CNR1 | |
| SCHEMBL31429324 | 0.73 | RPA1 (0.54) | SMPD1MARS1RPA1ALDH1A1MAPT | |
| SCHEMBL28554732 | 0.73 | MARS1 (0.61) | MARS1RPA1 | |
| SCHEMBL1738359 | 0.72 | RPA1 (0.52) | MARS1RPA1ALDH1A1MAPTHTT | |
| SCHEMBL570061 | 0.71 | RPA1 (0.63) | MARS1RPA1ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084467-B2 | For both CB1 and CB2 receptor sites; 3-(N-hetero)amido-5-phenyl pyrazoles; memory deficits associated with aging or nervous system disorders, obesity, schizophrenia, septic shock | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-7745440-B2 | Pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2010-06-29 | — | — | US | disclosed |
| US-20060100208-A1 | Pyrazole derivatives as cannabinoid receptor antagonists | UNIVERSITY OF CONNECTICUT | 2006-05-11 | — | — | US | disclosed |
| US-20060030563-A1 | Novel pyrazole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT | 2006-02-09 | — | — | US | disclosed |
| EP-1224173-B1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | UNIV CONNECTICUT (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1224173-A4 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | UNIV CONNECTICUT (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1224173-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | THE UNIVERSITY OF CONNECTICUT (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029007-A1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | UNIVERSITY OF CONNECTICUT (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030563-A1 | Novel pyrazole analogs acting on cannabinoid receptors | CNR1, CNR2, P2RY1 | SMPD1 1354/4885CNR1 1/4885MARS1 3898/4885 |
| US-20060100208-A1 | Pyrazole derivatives as cannabinoid receptor antagonists | CNR1, CNR2, P2RY1 | SMPD1 1272/4885CNR1 1/4885MARS1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.